C4 Therapeutics, Inc. (CCCC) Financials

CCCC Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 359.4 million 112.1 million
March 31, 2026 328.9 million 94.6 million
Dec. 31, 2025 359.1 million 102.5 million
Sept. 30, 2025 265.5 million 111.1 million

CCCC Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -1.6 million 3.0 million
March 31, 2026 -30.0 million 2.7 million
Dec. 31, 2025 -22.2 million 4.0 million
Sept. 30, 2025 -31.6 million 4.6 million

CCCC Net Income

No data available :(

CCCC Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 253.7 million - 56.9 million
March 31, 2026 235.7 million - 51.9 million
Dec. 31, 2025 248.5 million - 60.0 million
Sept. 30, 2025 191.9 million - 61.5 million

CCCC Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 130.7 million
March 31, 2026 126.1 million
Dec. 31, 2025 116.8 million
Sept. 30, 2025 72.6 million

CCCC Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 37000 24.5 million 8.6 million -
March 31, 2026 64000 24.6 million 7.5 million -1.8 million
Dec. 31, 2025 11000 25.0 million 9.2 million -
Sept. 30, 2025 411000 26.0 million 8.9 million -

CCCC Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 6.6 million -
March 31, 2026 6.2 million 1.8 million
Dec. 31, 2025 11.0 million 1.8 million
Sept. 30, 2025 11.2 million -

CCCC

Price: $2.76

52 week price:
1.69
5.17

Earnings Per Share: -0.91 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 914600

Market Capitalization: 330.6 million

Links: